WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:

two anti-chondrogensis agents.

2. The pharmaceutical composition of claim 1, wherein the anti-chondrogenesis agent is an anti-muscarinic agent.
3. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent is atropine.
4. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent comprises about 0.001% to about 1% by weight atropine.
5. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent comprises about 0.005% to about 0.05% by weight atropine.
6. The pharmaceutical composition of claim 1, wherein the anti-chondrogensis agent is a non-steroidal anti-inflammatory drug (NSAID).
7. The pharmaceutical composition of claim 6, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.
8. The pharmaceutical composition of claim 6, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.
9. The pharmaceutical composition of claim 6, wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac.
10. A method for treating myopia, comprising administering an effective amount of one or more anti-chondrogenesis agents to a myopia subject.
11. The method of claim 10, wherein the anti-chondrogenesis agent is NSAID.
12. The method of claim 11, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

13. The method of claim 11, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.
14. The method of claim 11, wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac.
15. The method of claim 10, wherein the anti-chondrogenesis agent is an anti-muscarinic agent.
16. The method of claim 15, wherein the anti-muscarinic agent is atropine.
17. The method of claim 15, wherein the anti-muscarinic agent comprises about 0.001% to about 1% by weight atropine.
18. The method of claim 15, wherein the anti-muscarinic agent comprises about 0.005% to about 0.05% by weight atropine.

CLAIMS

1. A pharmaceutical composition, comprising:

two anti-chondrogensis agents.

2. The pharmaceutical composition of claim 1, wherein the anti-chondrogenesis agent is an anti-muscarinic agent.

3. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent is atropine.

4. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent comprises about 0.001% to about 1% by weight atropine.

5. The pharmaceutical composition of claim 2, wherein the anti-muscarinic agent comprises about 0.005% to about 0.05% by weight atropine.

6. The pharmaceutical composition of claim 1, wherein the anti-chondrogensis agent is a non-steroidal anti-inflammatory drug (NSAID).

7. The pharmaceutical composition of claim 6, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

8. The pharmaceutical composition of claim 6, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.

9. The pharmaceutical composition of claim 6, wherein the NSAID comprises about

0.01% to about 0.2% by weight diclofenac.

10. The use of a pharmaceutical composition comprising one or more anti-chondrogensis agents in the manufacture of a medicament for the treatment of myopia.

11. The use of claim 10, wherein the anti-chondrogenesis agent is NSAID.

12. The use of claim 11, wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof.

13. The use of claim 11, wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac.

14. The use of claim 11, wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac.

15. The use of claim 10, wherein the anti-chondrogenesis agent is an anti-muscarinic agent.

16. The use of claim 15, wherein the anti-muscarinic agent is about 0.001% to about 1% by weight atropine.

17. The use of claim 15, wherein the anti-muscarinic agent is about 0.005% to about 0.05% by weight atropine.